Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis...
🤝 Lilly's Zepbound plus Taltz combo: The company said the drugs, when taken together, helped 27.1% of patients with plaque psoriasis and obesity (or who were overweight) achieve full skin clearance ...
View ArticleReversal on Moderna's flu application follows atypical path through FDA
The decision by the FDA on Wednesday to reverse course and review Moderna's flu vaccine application was the result of a meeting Tuesday between an unusual group of senior FDA leaders and ...
View ArticleUpdated: Novartis signs macrocyclic deal with Unnatural Products
Novartis will pay $100 million in upfront and pre-IND milestone payments to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease...
View ArticleCharles River highlights increase in demand as tariff uncertainties fade
Charles River Laboratories said demand for its services is building back up after nearly a year of uncertainty around tariffs and drug pricing. With “tariff stuff being sort of over, and whatever...
View ArticleJ&J pours $1B into new cell therapy site in Pennsylvania
Johnson & Johnson said it will spend more than $1 billion to build a cell therapy manufacturing plant in Pennsylvania as part of its broader commitment unveiled last year to invest more ...
View ArticlePharma is done negotiating as Trump pushes to codify deals
After Pfizer became the first drugmaker to voluntarily make pricing concessions to President Donald Trump, CEO Albert Bourla had to sell a skeptical board of industry peers on what exactly the benefit...
View ArticleSenate health committee chair plots future FDA changes
Sen. Bill Cassidy (R-LA), chairman of the Senate HELP committee, unveiled new proposals on how the FDA can improve the drug approval process, US competitiveness with China, use of real-world data and...
View ArticleWhy clinical AI startup Kintsugi shut down
Kintsugi promised to use AI as a screening tool to detect signs of depression and anxiety in people’s voices during routine doctors' appointments, backed by high-profile investors like Insight...
View ArticleJ&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s...
Johnson & Johnson has paused enrollment in the Phase 2b trial of its Alzheimer’s disease candidate, and the stock {$ACIU} of its partner AC Immune closed down about 10% on Wednesday. The asset is...
View ArticleAltesa raises $75M for oral respiratory med
Altesa BioSciences has closed a $75 million Series B, enough to finance a Phase 2b study of its oral respiratory drug meant to prevent serious COPD exacerbations. The raise announced Thursday adds...
View ArticleHims to buy Australia’s Eucalyptus for $240M upfront in global push
In a bid to build out its global presence, Hims is buying Australian digital health company Eucalyptus in a deal worth $240 million upfront. The deal announced Thursday morning would allow Hims to...
View ArticleSanofi to expand in India; Stada invests $100M in Saudi Arabia
Sanofi is further boosting its presence in India with an expansion of its Global Capability Centre in Hyderabad. The move will add 1,900 new jobs, which will bring the total number ...
View ArticleBiogen stops part of an MS trial; Merck reports more Enflonsia data
Plus, news about Compass Pathways, Starget Pharma and Ten63 Therapeutics: 🛑 Biogen halts combo portion of MS trial: The biotech is not moving forward with the second part of the
View ArticleObesity biotech Verdiva plans big year of data, explores deals
Pfizer’s purchase of obesity biotech Metsera last year threw the spotlight on long-acting weight loss drugs. And the launch of Novo Nordisk’s Wegovy pill in January did the same ...
View ArticleFDA formalizes one pivotal trial policy via NEJM perspective
Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two...
View ArticleTeva beats Corcept in appeals fight over generic Cushing's syndrome drug
Teva scored a win after a federal appeals court held that its generic Cushing’s syndrome drug doesn’t infringe Corcept Therapeutics' patents. The US Court of Appeals for the Federal Circuit
View ArticleWhen a health tech startup gets stuck in regulatory limbo
I’ve been seeing more companies offering AI for healthcare tasks that go beyond administrative work into clinical areas, such as suggesting diagnoses. But despite the funding frenzy over AI, it's been...
View ArticleAbbVie, PhRMA can proceed with 340B case in Hawaii
A federal judge is allowing AbbVie and PhRMA to proceed with most of their claims against a Hawaii state law that regulates how 340B-discounted drugs are distributed. Thursday's decision dealt an ...
View ArticleGrail's cancer test misses primary study goal in UK study
Grail on Thursday reported that its cancer test showed promise but failed to meet its primary goal in a large UK study, tanking the company's stock in after-hours trading. Grail {$GRAL} was trading...
View ArticleSanofi appoints specialty care head; Biogen chair to retire in June
→ As Sanofi looks ahead to the Belén Garijo era, the French pharma will also have a new head of specialty care on March 1. Brian Foard
View Article